Summary: In adults with obesity, a phase 1 randomised mechanistic study found that tirzepatide had no detectable effect on metabolic adaptation (sleeping metabolic rate and 24-hour energy expenditure were comparable to placebo after adjusting for body composition) but increased fat oxidation and reduced appetite and calorie intake during an ad libitum test meal. The attenuation of metabolic adaptation was seen only in calorie-restricted obese mice, not in humans.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with obesity in a phase 1 clinical trial (NCT04081337), accompanied by a parallel preclinical study in calorie-restricted, diet-induced obese mice. Single-centre mechanistic study conducted in the United States. |
| Intervention | Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, administered to assess energy expenditure, fat oxidation, and energy intake. |
| Comparison | Placebo (human trial); vehicle-treated and pair-fed controls (mouse study). |
| Outcome | In humans, tirzepatide had no detectable impact on metabolic adaptation: reductions in sleeping metabolic rate and 24-hour energy expenditure were comparable to placebo after adjustment for body composition. It increased fat oxidation and reduced appetite and calorie intake during an ad libitum test meal versus placebo. In mice, tirzepatide attenuated the fall in energy expenditure seen in vehicle-treated and pair-fed animals and lowered the respiratory exchange ratio, indicating increased fat oxidation. The abstract reports no effect sizes, 95% confidence intervals, or p-values, and no efficacy weight-loss endpoint for this phase 1 study. |
Expert Commentary
This is a mechanistic study rather than an efficacy trial, and it should be read as such. The headline weight loss attributed to tirzepatide comes from the earlier phase 3 programme; what this phase 1 work adds is a plausible mechanism, namely a shift toward fat oxidation alongside reduced appetite and energy intake, rather than the preservation of energy expenditure that some had hypothesised. The species divergence is the most important nuance. In calorie-restricted mice, metabolic adaptation was attenuated, but in humans it was not, so the mouse finding should not be carried over to patients. The principal limitation is the small, short-term phase 1 design, which was not powered to detect modest differences in energy expenditure and reports no effect sizes or confidence intervals; a negative metabolic-adaptation result here is best read as no clear signal rather than proven absence of effect. The trial was sponsored by the manufacturer, with several authors employed by the company, which warrants the usual caution even though the mechanistic findings are biologically reasonable. Can I use this with my patients? Not as a new clinical claim. For an adult already prescribed tirzepatide for obesity, this study helps explain why the drug works, but it changes no dosing, monitoring, or counselling. I would welcome a larger, independent chamber study with reported effect estimates to confirm the human fat-oxidation signal.
References
Ravussin E, Sanchez-Delgado G, Martin CK, Beyl RA, Greenway FL, O’Farrell LS, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025;37(5):1060-1074.e4. doi:10.1016/j.cmet.2025.03.011
